Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 24, 2014, Pages 8907-8912

  Tang, Xiao Han ^a   Osei Sarfo, Kwame ^a   Urvalek, Alison M ^a   Zhang, Tuo ^a   Scognamiglio, Theresa ^a   Gudas, Lorraine J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer prevention; Oral cancer; Retinoic acid receptor gamma agonist; Retinoid x receptor; Tongue squamous cell carcinoma

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; BETA CATENIN; BEXAROTENE; CD 1530; GELATINASE B; REACTIVE OXYGEN METABOLITE; RETINOIC ACID RECEPTOR GAMMA; RETINOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RNA SEQUENCE; TRIACYLGLYCEROL BLOOD LEVEL;

CANCER PREVENTION; ORAL CANCER; RETINOIC ACID RECEPTOR GAMMA AGONIST; RETINOID X RECEPTOR; TONGUE SQUAMOUS CELL CARCINOMA;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; ANTICARCINOGENIC AGENTS; BENZOATES; BETA CATENIN; CARCINOGENESIS; CARCINOGENS; CELL CYCLE; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; FEMALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MOUTH NEOPLASMS; NAPHTHOLS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, RETINOIC ACID; RETINOIDS; TETRAHYDRONAPHTHALENES; TRIGLYCERIDES;

EID: 84902593770     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404828111     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30.
2. Binnie WH, Rankin KV, Mackenzie IC (1983) Etiology of oral squamous cell carcinoma. J Oral Pathol 12(1):11-29. (Pubitemid 13110094)
3. Lippman SM, Sudbø J, Hong WK (2005) Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23(2):346-356. (Pubitemid 46206883)
4. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359(11):1143-1154.
5. Gudas LJ, Sporn MB, Roberts AB (1994) Cell biology and biochemistry of the retinoids. The Retinoids: Biology, Chemistry, and Medicine, eds Sporn MB, Roberts AB, Goodman DS (Raven Press, New York), pp 443-520.
6. Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10(9):940-954.
7. Mongan NP, Gudas LJ (2007) Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 75(9):853-870. (Pubitemid 350086170)
8. Tang XH, Gudas LJ (2011) Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 6:345-364.
9. Connolly RM, Nguyen NK, Sukumar S (2013) Molecular pathways: Current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 19(7):1651-1659.
10. Lippman SM, et al. (1993) Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328(1):15-20. (Pubitemid 23011466)
11. Tang XH, Albert M, Scognamiglio T, Gudas LJ (2009) A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Cancer Prev Res (Phila) 2(12):1100-1110.
12. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ (2004) Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 10(1 Pt 1):301-313. (Pubitemid 38114193)
13. Vitale-Cross L, et al. (2009) Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. Cancer Prev Res (Phila) 2(5):419-422.
14. Tang XH, Scognamiglio T, Gudas LJ (2013) Basal stem cells contribute to squamous cell carcinomas in the oral cavity. Carcinogenesis 34(5):1158-1164.
15. Boehm MF, et al. (1995) Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 38(16):3146-3155.
16. Dragnev KH, et al. (2007) A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 13(6):1794-1800. (Pubitemid 46952948)
17. Dragnev KH, et al. (2011) Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) 4(6):818- 828.
18. Gniadecki R, et al. (2007) The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 157(3):433-440. (Pubitemid 47256108)
19. Chen CF, Goyette P, Lohnes D (2004) RARgamma acts as a tumor suppressor in mouse keratinocytes. Oncogene 23(31):5350-5359. (Pubitemid 39005810)
20. Shimono K, et al. (2011) Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med 17(4):454-460.
21. Janakiram NB, et al. (2012) Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia 14(2):159-168.
22. Tang XH, Su D, Albert M, Scognamiglio T, Gudas LJ (2009) Overexpression of lecithin: retinol acyltransferase in the epithelial basal layer makes mice more sensitive to oral cavity carcinogenesis induced by a carcinogen. Cancer Biol Ther 8(13):1212-1213.
23. Gillespie RF, Gudas LJ (2007) Retinoic acid receptor isotype specificity in F9 terato-carcinoma stem cells results from the differential recruitment of coregulators to retinoic response elements. J Biol Chem 282(46):33421-33434. (Pubitemid 350159505)
24. Sherr CJ (2004) Principles of tumor suppression. Cell 116(2):235-246.
25. Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30(11):630-641. (Pubitemid 41540083)
26. Sherr CJ (2000-2001) Cell cycle control and cancer. Harvey Lect 96:73-92.
27. Maiorano D, Lutzmann M, Méchali M (2006) MCM proteins and DNA replication. Curr Opin Cell Biol 18(2):130-136. (Pubitemid 43375879)
28. Munshi HG, Stack MS (2006) Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev 25(1):45-56. (Pubitemid 43723981)
29. Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244(2):143-163. (Pubitemid 44508708)
30. Smith A, Teknos TN, Pan Q (2013) Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol 49(4):287-292.
31. Aragonés J, Fraisl P, Baes M, Carmeliet P (2009) Oxygen sensors at the crossroad of metabolism. Cell Metab 9(1):11-22.
32. Brahimi-Horn MC, Bellot G, Pouysségur J (2011) Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21(1):67-72.
33. Tello D, et al. (2011) Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity. Cell Metab 14(6):768-779.
34. Khan Z, et al. (2011) Biology of Cox-2: An application in cancer therapeutics. Curr Drug Targets 12(7):1082-1093.
35. Hanafi R, et al. (2012) Oxidative stress based-biomarkers in oral carcinogenesis: How far have we gone? Curr Mol Med 12(6):698-703.
36. Ullery JC, Marnett LJ (2012) Protein modification by oxidized phospholipids and hydrolytically released lipid electrophiles: Investigating cellular responses. Biochim Biophys Acta 1818(10):2424-2435.
37. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 49(11):1603-1616.
38. Song J, Chang I, Chen Z, Kang M, Wang CY (2010) Characterization of side populations in HNSCC: Highly invasive, chemoresistant and abnormal Wnt signaling. PLoS ONE 5(7):e11456.
39. Pannone G, et al. (2010) WNT pathway in oral cancer: Epigenetic inactivation of WNT-inhibitors. Oncol Rep 24(4):1035-1041.
40. Osei-Sarfo K, Tang XH, Urvalek AM, Scognamiglio T, Gudas LJ (2013) The molecular features of tongue epithelium treated with the carcinogen 4-nitroquinoline-1-oxide and alcohol as a model for HNSCC. Carcinogenesis 34(11):2673-2681.
41. Fan HX, Li HX, Chen D, Gao ZX, Zheng JH (2012) Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: Relationships and prognostic implications. J Exp Clin Cancer Res 31:90.
42. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS (2007) Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 29(6):564-572. (Pubitemid 47324773)
43. Pérez E, Bourguet W, Gronemeyer H, de Lera AR (2012) Modulation of RXR function through ligand design. Biochim Biophys Acta 1821(1):57-69.
44. Germain P, et al. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58(4):760-772. (Pubitemid 44833744)
45. Ouamrane L, Larrieu G, Gauthier B, Pineau T (2003) RXR activators molecular signalling: involvement of a PPAR alpha-dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart. Br J Pharmacol 138(5):845-854. (Pubitemid 36390641)
46. Shilkaitis A, Bratescu L, Green A, Yamada T, Christov K (2013) Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesis. Cancer Prev Res (Phila) 6(4):299-308.
47. Abba MC, et al. (2009) Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer Prev Res (Phila) 2(2):175-184.
48. Kim HT, et al. (2006) Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 66(24):12009-12018.
49. Hatoum A, El-Sabban ME, Khoury J, Yuspa SH, Darwiche N (2001) Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. Carcinogenesis 22(12):1955-1963. (Pubitemid 34065389)
50. Kanojia D, Vaidya MM (2006) 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 42(7):655-667. (Pubitemid 44094232)
51. Nunoshiba T, Demple B (1993) Potent intracellular oxidative stress exerted by the carcinogen 4-nitroquinoline-N-oxide. Cancer Res 53(14):3250-3252. (Pubitemid 23223291)
52. Xiao JH, et al. (2003) Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 278(32):29954-29962.
53. Yanagitani A, et al. (2004) Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 40(2):366-375. (Pubitemid 39062854)
54. Papi A, Rocchi P, Ferreri AM, Guerra F, Orlandi M (2009) Enhanced effects of PPAR-gamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol Rep 21(4):1083-1089.
55. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3): 399-408.
56. Eckert AW, et al. (2010) Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 39(4):313-317.